Terms: = Uterine cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Clinical Outcome
12 results:
1. clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract] [Full Text] [Related]
2. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL; Thomson JP; Stanley B; Churchman M; Meynert AM; Rye T; Bartos C; Iida Y; Croy I; Mackean M; Nussey F; Okamoto A; Semple CA; Gourley C; Herrington CS
Nat Commun; 2020 Oct; 11(1):4995. PubMed ID: 33020491
[TBL] [Abstract] [Full Text] [Related]
3. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
Yoshimoto Y; Sasaki Y; Murata K; Noda SE; Miyasaka Y; Hamamoto J; Furuya M; Hirato J; Suzuki Y; Ohno T; Tokino T; Oike T; Nakano T
Gynecol Oncol; 2020 Nov; 159(2):546-553. PubMed ID: 32951893
[TBL] [Abstract] [Full Text] [Related]
4. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
5. Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and clinical outcome.
Lu X; Jiang L; Zhang L; Zhu Y; Hu W; Wang J; Ruan X; Xu Z; Meng X; Gao J; Su X; Yan F
Neoplasia; 2019 Jun; 21(6):591-601. PubMed ID: 31055200
[TBL] [Abstract] [Full Text] [Related]
6. DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.
Bean GR; Anderson J; Sangoi AR; Krings G; Garg K
Mod Pathol; 2019 Feb; 32(2):280-289. PubMed ID: 30266945
[TBL] [Abstract] [Full Text] [Related]
7. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Yu Y; Hall T; Eathiraj S; Wick MJ; Schwartz B; Abbadessa G
Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
[TBL] [Abstract] [Full Text] [Related]
8. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract] [Full Text] [Related]
9. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
[TBL] [Abstract] [Full Text] [Related]
10. outcomes of patients with metastatic cervical cancer in a phase I clinical trials program.
Hou MM; Liu X; Wheler J; Naing A; Hong D; Bodurka D; Schmeler K; Tsimberidou A; Janku F; Zinner R; Piha-Paul S; Hu CY; Lu K; Kurzrock R; Fu S
Anticancer Res; 2014 May; 34(5):2349-55. PubMed ID: 24778042
[TBL] [Abstract] [Full Text] [Related]
11. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical Trials Group.
Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
[TBL] [Abstract] [Full Text] [Related]
12. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract] [Full Text] [Related]
